EUVIMEDEUVIMED entdecken
Open Access

Reflectance Confocal Microscopy–Optical Coherence Tomography‐Guided Laser Ablation of Low‐Risk Basal Cell Carcinoma: A Long‐Term Prospective Follow‐Up Study

Noa Kremer iD, Miguel Cordova iD, Aditi Sahu, Larissa M Pastore iD, Rachel Manci iD, Zaeem H Nazir, Rozina Zeidan, Cristian Navarrete-Dechent iD, Oriol Yélamos iD, Stephen W Dusza iD, Nicusor Iftimia iD, Melissa Gill iD und 3 weitere

Lasers in Surgery and Medicine · 2026

DOI: 10.1002/lsm.70201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lasers in Surgery and Medicine, 2026. Verfasst von Noa Kremer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Tomography, Optical Coherence, Laser Therapy, Basal Cell Carcinoma, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute Cancer Center, NIBIB NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The primary objective was to evaluate the long‐term recurrence rate following RCM–OCT‐guided laser ablation of basal cell carcinomas (BCCs). The secondary objective was to assess patient‐reported outcomes, including willingness to undergo the treatment again, scar acceptability, and adverse effects.

Methods

A prospective cohort study evaluated 104 patients with 148 BCCs (2017–2021). Low risk BCC subtypes and with tumor depth of ≤ 300 µm were determined using RCM–OCT, and eligible lesions underwent same‐day Er:YAG laser ablation with immediate post‐treatment imaging to confirm clearance. Patients underwent clinical and RCM–OCT or RCM surveillance at 6 and 12 months and annually thereafter to assess recurrence. A patient‐reported questionnaire was conducted in 2023.

Results

Fifty‐eight lesions (39.2%) in 39 patients met the criteria for laser ablation. Most lesions were located on the trunk (29/58, 50.0%), with median tumor depth and lesion size of 200 µm and 9.8 mm, respectively. Immediate post‐ablation RCM–OCT demonstrated imaging‐defined complete clearance after a single session in 53/58 lesions (91.4%). Residual tumors (5/58, 8.6%) were successfully treated during the same visit. Fifty‐four of 58 lesions (93.1%) had at least 6 months of follow‐up (median 32 months; min/max 8–70). One recurrence occurred at 53 months and was successfully retreated, corresponding to 1.04 recurrences per 100 person‐years of follow‐up. The patient‐reported questionnaire response rate was 79.5% (31/39). Overall, 96.8% (30/31) reported acceptable scar appearance, 83.9% (26/31) were likely to choose laser ablation again (Score 1–2 of 5), and 9.7% (3/31) reported mild, transient side effects.

Conclusions

RCM–OCT‐guided Er:YAG laser ablation offers a “one‐stop” treatment approach for selected low‐risk BCCs, demonstrating low long‐term recurrence rates and high patient satisfaction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tomography, Optical CoherenceLaser TherapyBasal Cell CarcinomaSkin NeoplasmsLasers, Solid-StateSurgery, Computer-AssistedHumansProspective StudiesFemaleMaleFollow-Up StudiesAgedMiddle AgedMicroscopy, ConfocalNeoplasm Recurrence, LocalAged, 80 and over

Stichwörter der Autor:innen

Er:YAG laserimaging‐guided laser treatmentlow‐risk basal cell carcinomaoptical coherence tomographyreflectance confocal microscopy“one stop” treatment approach

Autor:innen und Institutionen

  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Dermatology, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Department of Dermatology, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
  • Physical Sciences Inc, Andover, Massachusetts, USA.

ORCID-Profile: Noa Kremer, Miguel Cordova, Larissa M Pastore, Rachel Manci, Cristian Navarrete-Dechent, Oriol Yélamos, Stephen W Dusza, Nicusor Iftimia, Melissa Gill, Ashfaq A Marghoob, Milind Rajadhyaksha, Chih-Shan Jason Chen

Förderung

  • NCI NIH HHS
  • National Cancer Institute Cancer Center
  • NIBIB NIH HHS

Zitieren

APA

Kremer, N., Cordova, M., Sahu, A., Pastore, L. M., Manci, R., Nazir, Z. H., Zeidan, R., Navarrete-Dechent, C., Yélamos, O., Dusza, S. W., Iftimia, N., Gill, M., Marghoob, A. A., Rajadhyaksha, M., & Chen, C. J. (2026). Reflectance Confocal Microscopy–Optical Coherence Tomography‐Guided Laser Ablation of Low‐Risk Basal Cell Carcinoma: A Long‐Term Prospective Follow‐Up Study. Lasers in Surgery and Medicine. https://doi.org/10.1002/lsm.70201

Vancouver

Kremer N, Cordova M, Sahu A, Pastore LM, Manci R, Nazir ZH, et al. Reflectance Confocal Microscopy–Optical Coherence Tomography‐Guided Laser Ablation of Low‐Risk Basal Cell Carcinoma: A Long‐Term Prospective Follow‐Up Study. Lasers in Surgery and Medicine. 2026. doi:10.1002/lsm.70201

BibTeX
@article{Kremer2026,
  author = {Kremer, Noa and Cordova, Miguel and Sahu, Aditi and Pastore, Larissa M and Manci, Rachel and Nazir, Zaeem H and Zeidan, Rozina and Navarrete-Dechent, Cristian and Yélamos, Oriol and Dusza, Stephen W and Iftimia, Nicusor and Gill, Melissa and Marghoob, Ashfaq A and Rajadhyaksha, Milind and Chen, Chih-Shan Jason},
  title = {Reflectance Confocal Microscopy–Optical Coherence Tomography‐Guided Laser Ablation of Low‐Risk Basal Cell Carcinoma: A Long‐Term Prospective Follow‐Up Study},
  journal = {Lasers in Surgery and Medicine},
  year = {2026},
  doi = {10.1002/lsm.70201}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche